Cargando…
Data-driven translational prostate cancer research: from biomarker discovery to clinical decision
Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060655/ https://www.ncbi.nlm.nih.gov/pubmed/32143723 http://dx.doi.org/10.1186/s12967-020-02281-4 |
_version_ | 1783504279653318656 |
---|---|
author | Lin, Yuxin Zhao, Xiaojun Miao, Zhijun Ling, Zhixin Wei, Xuedong Pu, Jinxian Hou, Jianquan Shen, Bairong |
author_facet | Lin, Yuxin Zhao, Xiaojun Miao, Zhijun Ling, Zhixin Wei, Xuedong Pu, Jinxian Hou, Jianquan Shen, Bairong |
author_sort | Lin, Yuxin |
collection | PubMed |
description | Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided. |
format | Online Article Text |
id | pubmed-7060655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70606552020-03-11 Data-driven translational prostate cancer research: from biomarker discovery to clinical decision Lin, Yuxin Zhao, Xiaojun Miao, Zhijun Ling, Zhixin Wei, Xuedong Pu, Jinxian Hou, Jianquan Shen, Bairong J Transl Med Review Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided. BioMed Central 2020-03-07 /pmc/articles/PMC7060655/ /pubmed/32143723 http://dx.doi.org/10.1186/s12967-020-02281-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Lin, Yuxin Zhao, Xiaojun Miao, Zhijun Ling, Zhixin Wei, Xuedong Pu, Jinxian Hou, Jianquan Shen, Bairong Data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
title | Data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
title_full | Data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
title_fullStr | Data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
title_full_unstemmed | Data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
title_short | Data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
title_sort | data-driven translational prostate cancer research: from biomarker discovery to clinical decision |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060655/ https://www.ncbi.nlm.nih.gov/pubmed/32143723 http://dx.doi.org/10.1186/s12967-020-02281-4 |
work_keys_str_mv | AT linyuxin datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT zhaoxiaojun datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT miaozhijun datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT lingzhixin datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT weixuedong datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT pujinxian datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT houjianquan datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision AT shenbairong datadriventranslationalprostatecancerresearchfrombiomarkerdiscoverytoclinicaldecision |